Table 2.

Prevalence of metabolic complicationsa in the cohort

Prevalence of ComplicationsPrevalence of Treatment among Patients with Complications
n%n%
Hyperparathyroidism610598714
Anemia210203718
Acidosis160153522
Hyperkalemia176178749
Hyperphosphatemia8483238
  • a Hyperparathyroidism was defined as a PTH >60 pg/ml or active vitamin D treatment; anemia was defined as Hb<110 g/L according to K/DOQI-based criteria or erythropoiesis-stimulating agent (ESA) treatment; acidosis was defined a tCO2 <22 mmol/L) or bicarbonate treatment; hyperkalemia was defined as plasma potassium concentration >5 mmol/L or ion exchange resin treatment; hyperphosphatemia was defined as plasma phosphate concentration >4.3 mg/dl (1.38 mmol/L) or phosphate binder treatment.